Gary Blick

Summary

Publications

  1. doi request reprint Long-term efficacy and safety of once-daily fosamprenavir 1400 mg boosted by ritonavir 100 mg: the BOLD100 study
    G Blick
    Circle Medical LLD, Norwalk, CT 06851, USA
    Int J STD AIDS 23:e18-22. 2012
  2. ncbi request reprint The probable source of both the primary multidrug-resistant (MDR) HIV-1 strain found in a patient with rapid progression to AIDS and a second recombinant MDR strain found in a chronically HIV-1-infected patient
    Gary Blick
    Circle Medical LLC, Norwalk, CT 06851, USA
    J Infect Dis 195:1250-9. 2007
  3. ncbi request reprint Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST
    Francois Raffi
    University of Nantes, Nantes, France
    AIDS 21:1977-80. 2007
  4. ncbi request reprint Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis
    Jeffrey P Nadler
    Hillsborough County Health Department, University of South Florida, Tampa, FL 33602, USA
    AIDS 21:F1-10. 2007
  5. doi request reprint Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51)
    Sharon L Walmsley
    Division of Clinical Investigation and Human Physiology, University of Toronto, Toronto, ON, Canada
    J Acquir Immune Defic Syndr 47:429-40. 2008
  6. pmc Maraviroc for previously treated patients with R5 HIV-1 infection
    Roy M Gulick
    Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 359:1429-41. 2008
  7. doi request reprint Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
    Gerd Fatkenheuer
    Universitätsklinik Köln, Cologne, Germany
    N Engl J Med 359:1442-55. 2008

Collaborators

Detail Information

Publications7

  1. doi request reprint Long-term efficacy and safety of once-daily fosamprenavir 1400 mg boosted by ritonavir 100 mg: the BOLD100 study
    G Blick
    Circle Medical LLD, Norwalk, CT 06851, USA
    Int J STD AIDS 23:e18-22. 2012
    ..In conclusion, FPV/RTV 1400/100 mg QD-containing regimens remained effective long-term in all ARV-naïve and most PI-naïve and PI-experienced HIV-infected patients...
  2. ncbi request reprint The probable source of both the primary multidrug-resistant (MDR) HIV-1 strain found in a patient with rapid progression to AIDS and a second recombinant MDR strain found in a chronically HIV-1-infected patient
    Gary Blick
    Circle Medical LLC, Norwalk, CT 06851, USA
    J Infect Dis 195:1250-9. 2007
    ..The probable source of this HIV-1 (hereafter referred to as "CT01") and the development of a recombinant MDR HIV-1 in the source's partner (hereafter referred to as "CT02") are described...
  3. ncbi request reprint Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST
    Francois Raffi
    University of Nantes, Nantes, France
    AIDS 21:1977-80. 2007
    ..Observed increases in plasma tipranavir concentrations thus had no apparent effect on the risk of hepatotoxicity...
  4. ncbi request reprint Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis
    Jeffrey P Nadler
    Hillsborough County Health Department, University of South Florida, Tampa, FL 33602, USA
    AIDS 21:F1-10. 2007
    ....
  5. doi request reprint Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51)
    Sharon L Walmsley
    Division of Clinical Investigation and Human Physiology, University of Toronto, Toronto, ON, Canada
    J Acquir Immune Defic Syndr 47:429-40. 2008
    ..Given the limited treatment options for patients with high-level resistance, antiretroviral (ARV) regimens based on concomitant use of 2 ritonavir (RTV)-boosted protease inhibitors (PIs) were considered a therapeutic option...
  6. pmc Maraviroc for previously treated patients with R5 HIV-1 infection
    Roy M Gulick
    Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 359:1429-41. 2008
    ..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents...
  7. doi request reprint Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
    Gerd Fatkenheuer
    Universitätsklinik Köln, Cologne, Germany
    N Engl J Med 359:1442-55. 2008
    ....